Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did ...

Tumors were usually ductal carcinomas, estrogen- and progesterone-positive, stage I/II, and Grade 2/3, with a 5-month delay on average between initial signs and diagnostic imaging. Treatments followed ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...

What Is It, and Why Does It Matter? Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with ...

Overall survival in metastatic HER2-positive breast cancer varied by location of brain lesions. Patients with central nervous system (CNS)-only disease had a higher risk of CNS-related death, despite ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer. Antibody-drug conjugates, or ADCs, have had a tremendous impact on the ...

This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...

EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...